UK CMA Confirms Akzo Nobel-Axalta Merger Notice Meets Enterprise Act 2002 Requirements, Sets November 11, 2026 Deadline For Phase 2 Investigation Decision
https://www.gov.uk/cma-cases/akzonobel-slash-axalta-merger-inquiry
Stocks · News reference
Reported Earlier, AkzoNobel And Axalta Lower Non-Executive Director Approval Threshold To Two-Thirds From 75% For Key Decisions During Initial Three-Year Period
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Global Pharmaceutical Surfactants Market Size/Share Worth USD 6.93 Billion by 2035 at a 4.42% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
The global pharmaceutical surfactants market was valued at USD 4.5 billion in 2025 and is projected to reach USD 6.93 billion by 2035, growing at a CAGR of 4.42%. The market is driven by increasing demand for improved drug formulation, delivery systems, and expanding healthcare infrastructure. Non-ionic surfactants currently hold the largest market share, while Asia-Pacific is expected to be the fastest-growing region.
AkzoNobel, Axalta Coating Systems Announce Axanzo As Name Of New Combined Entity After Merger; New Entity To Trade Under AXZ Ticker On NYSE Post-Closing
Barclays Initiates Coverage On Axalta Coating Systems with Overweight Rating, Announces Price Target of $45
'Conditional EU antitrust approval expected for AkzoNobel, Axalta deal, sources say' - Reuters
UBS Maintains Neutral on Axalta Coating Systems, Lowers Price Target to $36
UBS analyst Joshua Spector maintains Axalta Coating Systems (NYSE:AXTA) with a Neutral and lowers the price target from $39 to $36.